Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells

(2017) Chun-Yu Liu et al.   Molecular Oncology

Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase

(2017) Seung Baek et al.   MOLECULES

Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1

(2017) Shiyu Song et al.   Cell Death & Disease

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

(2017) Ming-Hung Hu et al.   Oncotarget

Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma

(2017) Asma Beldi-Ferchiou et al.   PLoS One

Strategies and Approaches of Targeting STAT3 for Cancer Treatment

(2016) Steffanie L. Furtek et al.   ACS Chemical Biology

Novel targets and interaction partners of mutant p53 Gain-Of-Function

(2016) Lydia Aschauer et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

SHP-1: the next checkpoint target for cancer immunotherapy?

(2016) H. Angharad Watson et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy

(2016) Tzu-I Chao et al.   CANCER LETTERS

Novel STAT 3 inhibitors for treating gastric cancer

(2016) Catherine Cafferkey et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders

(2016) Yadhu Sharma et al.   IMMUNOLOGIC RESEARCH

Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling

(2016) Chao-Yuan Huang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations

(2016) Jessica L. Geiger et al.   ORAL ONCOLOGY

Targeting transcription factor STAT3 for cancer prevention and therapy

(2016) Edna Zhi Pei Chai et al.   PHARMACOLOGY & THERAPEUTICS

Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition

(2016) Tao Zhang et al.   Cell Death & Disease

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer

(2016) Li-Ching Fan et al.   Oncotarget

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis

(2016) Jung-Chen Su et al.   Scientific Reports

Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia

(2015) Hamid Ali Nagi Al-Jamal et al.   BMC CANCER

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

(2015) S J Thomas et al.   BRITISH JOURNAL OF CANCER

A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia

(2015) Ji Hoon Jung et al.   BRITISH JOURNAL OF PHARMACOLOGY

Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer

(2015) Matteo Santoni et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Wnt/β-catenin and LIF–Stat3 signaling pathways converge on Sp5 to promote mouse embryonic stem cell self-renewal

(2015) Shoudong Ye et al.   JOURNAL OF CELL SCIENCE

SHP-1 is a negative regulator of epithelial–mesenchymal transition in hepatocellular carcinoma

(2015) L-C Fan et al.   ONCOGENE

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer

(2015) Li-Ching Fan et al.   NEOPLASIA

SHP-1 is a target of regorafenib in colorectal cancer

(2015) Li-Ching Fan et al.   Oncotarget

Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors

(2014) Kodappully Sivaraman Siveen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells

(2014) Chun-Yu Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

(2014) Johanna C. Bendell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3

(2014) Chao-Yuan Huang et al.   CANCER LETTERS

RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells

(2014) J.-C. Su et al.   CARCINOGENESIS

STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma

(2014) W.-T. Tai et al.   CLINICAL CANCER RESEARCH

Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity

(2014) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

(2014) Jian Kong et al.   Molecular Cancer

Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model

(2014) Muthu K. Shanmugam et al.   MOLECULAR CARCINOGENESIS

Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma

(2014) Gang Peng et al.   Radiology and Oncology

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma

(2014) Jung-Chen Su et al.   NEOPLASIA

Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3

(2013) Aruljothi Subramaniam et al.   BRITISH JOURNAL OF PHARMACOLOGY

Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases

(2013) Jong Hyun Lee et al.   CANCER LETTERS

Trichosanthes kirilowiiEthanol Extract and Cucurbitacin D Inhibit Cell Growth and Induce Apoptosis through Inhibition of STAT3 Activity in Breast Cancer Cells

(2013) Soon Re Kim et al.   Evidence-based Complementary and Alternative Medicine

Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

(2013) Wei-Tien Tai et al.   HEPATOLOGY

Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer

(2013) Sarah R. Walker et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti-Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model

(2013) W.-T. Tai et al.   MOLECULAR CANCER THERAPEUTICS

NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer

(2013) Yihui Fan et al.   Protein & Cell

Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3

(2012) Kuen-Feng Chen et al.   BIOCHEMICAL PHARMACOLOGY

Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma

(2012) Aruljothi Subramaniam et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells

(2012) Yun-Hee Rhee et al.   BMC CANCER

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody

(2012) Kuen-Feng Chen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity

(2012) Kuen-Feng Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

(2012) XIAOCHUN WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Wnt/β-Catenin Pathway Cross-Talks with STAT3 Signaling to Regulate Survival of Retinal Pigment Epithelium Cells

(2012) Miryam A. Fragoso et al.   PLoS One

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

(2012) X. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter

(2011) Constance Zugowski et al.   BIOLOGICAL CHEMISTRY

Small Molecule Inhibitors of STAT3 for Cancer Therapy

(2011) M. Zhao et al.   CURRENT MEDICINAL CHEMISTRY

Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy

(2011) Daniela Masciocchi et al.   Future Medicinal Chemistry

Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells

(2011) Jang Choon Lee et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1

(2011) Peramaiyan Rajendran et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

(2011) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3

(2011) W.-T. Tai et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

(2010) Wei Zhao et al.   ANTI-CANCER DRUGS

γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent

(2010) Peramaiyan Rajendran et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

(2010) K.-F. Chen et al.   CLINICAL CANCER RESEARCH

Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells

(2010) Sun-Hee Kim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells

(2010) T. Iype et al.   JOURNAL OF IMMUNOLOGY

5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization

(2010) S. K. Sandur et al.   MOLECULAR CANCER RESEARCH

Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

(2010) Fan Yang et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

(2010) S. Huang et al.   MOLECULAR CANCER THERAPEUTICS

Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors

(2010) Luigi Insabato et al.   ONCOLOGY

Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer

(2009) Sergei I. Grivennikov et al.   CYTOKINE & GROWTH FACTOR REVIEWS

IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis

(2009) Julia Bollrath et al.   EMBO REPORTS

Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells

(2009) Manoj K. Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer

(2009) Helena Tassidis et al.   INTERNATIONAL JOURNAL OF CANCER

Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1

(2009) Ajaikumar B. Kunnumakkara et al.   MOLECULAR CANCER RESEARCH

Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer

(2009) Xiao-hua Tao et al.   PATHOLOGY & ONCOLOGY RESEARCH

β-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma

(2008) Shuang Yan et al.   CANCER LETTERS

Sorafenib

(2008) Dene Simpson et al.   DRUGS

Protein tyrosine phosphatases: regulatory mechanisms

(2008) Jeroen den Hertog et al.   FEBS Journal

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

(2008) F. Yang et al.   MOLECULAR CANCER THERAPEUTICS